Pandora A/S

Shares of Danish jewellery giant Pandora rose 5.6% in trading in Copenhagen on Thursday and continued higher after early trading on Friday. Despite weak guidance for 2026 and the suspension of share buybacks, the stock was supported by falling silver prices, Bloomberg <a href="https://www.bloomberg.com/news/articles/2026-02-05/pandora-sees-sales-slowing-pauses-buyback-as-silver-prices-bite?embedded-checkout=true#:~:text=Shares%20rose%20as%20much%20as%207.5%25%20in%20Copenhagen%20as%20silver%20prices%20tumbling%20outweighed%20concerns%20around%20guidance.">reported</a>. A day earlier, Pandora announced plans to partially shift away from the precious metal in favor of platinum-plated jewelry. On Friday, several analysts revised their target price on the company’s shares.

Pandora cuts sales guidance and pauses buybacks, but the stock is still rising

Janux Therapeutics, Inc.

Legend Biotech Corporation

4D Molecular Therapeutics, Inc.

Arcturus Therapeutics Holdings Inc.

Altimmune, Inc.

Black Diamond Therapeutics, Inc.

The global biotechnology market was valued at about $1.65 trillion in 2025 and is projected to grow to $5.22 trillion by 2034 at a compound annual growth rate of 13.67%, according to <a href="https://straitsresearch.com/report/biotechnology-market">Straits Research</a>. The U.S. market remains the largest globally: it was worth $552.39 billion in 2023 and is expected to reach $1.24 trillion by 2030. Insider Monkey has <a href="https://www.insidermonkey.com/blog/20-best-biotech-stocks-under-20-to-buy-now-1685703/">selected</a>&nbsp;20 biotech companies trading below $20 per share that are widely held by hedge funds.

Insider Monkey names 20 under-$20 biotech stocks popular with hedge funds

Brunello Cucinelli S.p.A.

Freedom Finance has issued a report rating shares of Italian luxury cashmere brand Brunello Cucinelli as a "buy," forecasting 34% upside from current levels. The firm notes that Brunello Cucinelli continues to deliver double-digit revenue growth and believes it is capable of expanding even amid turbulence in the luxury market.

Freedom says buy Italian luxury brand Brunello Cucinelli with 34% upside

Janux Therapeutics – a small-cap developer of prostate cancer therapies – has lost more than 65% of its market value over the past year. The steepest decline followed the release of data on one of the key candidates in the company’s pipeline. Despite this, Janux shares remain in the portfolios of BlackRock and investor Steve Cohen, according to its <a href="https://www.gurufocus.com/stock/JANX/ownership">Form 13F filing</a> as of the end of September. Wall Street analysts, for their part, continue to recommend buying the stock, expecting it could rise more than 300%.

Why biotech Janux, held by Blackrock and Steve Cohen, has consensus upside of 300%

Compass, Inc.

Anywhere Real Estate Inc.

Real estate broker Compass has evolved from a local startup into a company with a market capitalization of nearly $10 billion, offering a new approach to home sales based on the gradual release of listings from exclusive access into the open market. In January, Compass closed a merger with peer Anywhere Real Estate. The combined brokerage will control nearly 20% of U.S. home sales. Analysts believe the transaction could support Compass’ market position and share price, despite antitrust risks and persisting uncertainty around the housing market.

Real estate broker Compass closes Anywhere merger. What does this mean for the stock?

Contango Ore, Inc.

Dolly Varden Silver Corporation

Gold exploration and production company Contango ORE and silver miner Dolly Varden Silver <a href="https://www.contangoore.com/press-release/contango-ore-and-dolly-varden-silver-announce-merger-to-create-a-new-north-american-high-grade-mid-tier-silver-gold-producer-and-developer">announced</a>&nbsp;a merger in late December. The transaction will combine their assets in Alaska and British Columbia. Below is a summary of what investors need to know about the deal, the outlook for the combined company, and its key projects.

Gold and silver combine: Breaking down the Contango ORE/Dolly Varden merger

The Russell 2000, which tracks the performance of small and mid-cap stocks, reached a new all-time high on Thursday, January 8. Analysts view the move as an important signal for economic growth and see favorable prospects for smaller companies.

Russell 2000 hits another all-time high in 'broadening out of the market'

NioCorp Developments Ltd.

Shares of NioCorp Developments, which is engaged in exploration and development of mineral deposits in North America, have the potential to rise about 35%, Freedom Capital Markets analyst&nbsp;Vitaly Kononov argued in a recent initiation report on the company. He attributes the upside to long-term demand for critical minerals in the U.S. and progress at NioCorp’s flagship project, which is moving into the construction phase.

Freedom initiates on U.S. rare-earth miner NioCorp, sees 35% upside

Capricor Therapeutics, Inc.

Shares of biotech Capricor Therapeutics have <a href="https://www.marketwatch.com/investing/stock/capr?mod=search_symbol">surged</a>&nbsp;about 530% over the past month after the company reported positive results from a <a href="https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results">phase III trial</a>&nbsp;of its experimental therapy, deramiocel, for a rare disease called Duchenne muscular dystrophy. If the drug receives regulatory approval, Capricor shares could rise another 75%, according to Wall Street.

Lyudmila Milevskaya

Writes about:

Articles: 9